Mechanisms Underlying Bioactive Compounds Decline in Medicinal Blaps rhynchopetera During Artificial Rearing
Xizhe Yang1,2,3, Lamei Zhang1,3, Shengwen Zhou4
1Institute of Highland Forest Science, Chinese Academy of Forestry, Kunming, China.
Environmental Microbiology
|April 19, 2026
Summary
Artificial rearing of medicinal beetles like Blaps rhynchopetera reduces key bioactive compounds by altering gut microbes. Strategies informed by insect microbiomes are needed to maintain medicinal potency.
Area of Science:
- Insect biology
- Microbiome research
- Natural product chemistry
Background:
- Sustainable utilization of medicinal insects requires artificial rearing.
- Impact of rearing on insect bioactive compounds is not well understood.
Purpose of the Study:
- Investigate how artificial rearing affects the gut microbiota and metabolome of Blaps rhynchopetera.
- Determine the consequences for bioactive compound production.
Main Methods:
- Metabolomic analysis to identify altered metabolites.
- Network pharmacology to assess regulatory landscape changes.
- Metagenomic profiling to characterize gut microbiota shifts.
- Preliminary microbial reintroduction experiments.
Main Results:
- Rearing significantly altered 727 metabolites, with 436 (including analgesic/anti-inflammatory compounds) reduced.
- Rearing led to reduced gut microbial network complexity and a decline in Pseudomonadota.
- Pseudomonadota showed potential involvement in terpenoid biosynthesis.
Conclusions:
- Artificial rearing of Blaps rhynchopetera reshapes its gut microbiome and reduces medicinal compounds.
- A trade-off exists between rearing-induced microbial homogenization and medicinal potency.
- Microbiome-informed strategies are crucial for effective insect rearing.
More Related Videos
Related Concept Videos
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
320
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
320
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
374
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
374
01:22Bioavailability: Influencing Factors
644
Bioavailability refers to the extent and rate at which a drug reaches systemic circulation in its active form. Extent refers to the amount of the drug that makes it into circulation, while rate is the speed at which it enters circulation. It is influenced by several factors critical for optimizing drug formulations, dosing regimens, and therapeutic outcomes.Physicochemical properties of drugs and formulationsThe solubility, stability, and dissolution rate of a drug significantly impact its...
644
01:30Modified-Release Drug Delivery Systems: Bioavailability
152
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
152
01:19Factors Affecting Drug Biotransformation: Biological
889
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
889
01:20Desensitization and Tachyphylaxis
3.5K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.5K